GlassScriptPhysician profile
Ann Marie Rustia
NPI 1992039622
$5,504.68
in general payments reported to CMS, 2019-2025
34 companies · $1,100 in 2025
The $1,100 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,038 · 2022: $1,167 · 2023: $1,376 · 2024: $823 · 2025: $1,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,200 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,199.92 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $861.52 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $486.41 | 2021-2025 | |
| Novo Nordisk INC | $468.22 | 2021-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $443.58 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $417.65 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $374.17 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $360.92 | 2022-2025 | |
| Astellas Pharma US INC | $350.73 | 2023-2025 | Veozah |
| Amgen INC. | $241.90 | 2021-2025 | Repatha, Otezla, Repatha |
| Esperion Therapeutics, INC. | $172.40 | 2021-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $150.39 | 2021-2023 | |
| Pfizer INC. | $136.97 | 2021-2025 | |
| Dexcom, INC. | $118.74 | 2021-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $108.25 | 2021-2025 | Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.90 | 2022-2025 | Xifaxan, Trulance |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $84.43 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $67.33 | 2023-2024 | |
| Inspire Medical Systems, INC. | $61.23 | 2025 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $59.33 | 2021-2024 | Eliquis |
| Amarin Pharma, INC. | $54.87 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $44.54 | 2021 | |
| Sumitomo Pharma America, INC. | $43.09 | 2025 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $42.74 | 2022 | |
| Corcept Therapeutics | $38.87 | 2023-2024 | Korlym |
| Kowa Pharmaceuticals America, INC. | $33.51 | 2025 | Zoryve |
| Horizon Therapeutics Plc | $32.18 | 2022-2023 | Krystexxa |
| Exact Sciences Corporation | $26.90 | 2025 | Cologuard Collection Kit |
| Nevro Corp. | $23.58 | 2022 | |
| Sunovion Pharmaceuticals INC. | $23.40 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $21.65 | 2023 | Evkeeza |
| Seqirus USA INC | $19.34 | 2022 | |
| Idorsia Pharmaceuticals US INC | $18.93 | 2022 | |
| Medtronic, INC. | $15.30 | 2025 | Minimed 780g |
| Boston Scientific Corporation | $14.71 | 2023 | Wavewriter Alpha Prime 16 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Marie Rustia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.